Mesoblast Limited (ASX:MSB)

Last updated

Previous Close

Day Range

Year Range

Market Cap

Volume

P/E

-5.16

Historical Yield (%)

0.00

Short Sell (%)

9.79

GICS Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

GICS Sub-Industry Group

Biotechnology - 35201010

EPS

-21.72

ROE (%)

-0.17

ROA (%)

-0.09

EBITDA Margin (%)

-14.28

EBIT Margin (%)

-14.63

NPAT Margin (%)

-13.25

Inventory Turnover

0.00

Asset Turnover

0.01

Net Gearing (%)

0.14

Net Interest Cover

-6.84

Current Ratio

1.57

About Mesoblast Limited (MSB.AX)

Research & News

Stocks on the ASX To Watch This Week [11 July 22] July 11, 2022 - The Australian markets enjoyed a relief rally after the choppy conditions the previous week. Investors appeared to have discounted fears surrounding a recession and rate hikes, while positive news in the form of Chinese stimulus drew bulls back into action. This was despite a rate hike of 50 bps by the RBA, the first time… Continue Reading
Stocks on the ASX To Watch This Week [20 June 22] June 20, 2022 - The Australian markets continued their losing streak in line with global markets after last week’s bigger than expected inflation print in the US and a massive 75 basis point hike from the Fed. Markets were also spooked by power shortages in Australia and underwhelming employment data. The ASX200, ASX300, and ASX Ordinaries closed lower by… Continue Reading
Stocks on the ASX To Watch This Week [30 May 22] May 30, 2022 - The Australian market continued its winning streak this past week marked by the swearing-in of Prime Minister Anthony Albanese and solid retail spending in April. Other tailwinds included a sharp cut to China’s loan prime rate in order to stimulate economic activity, which by extension led to gains for domestic companies that export to China.… Continue Reading
Stocks on the ASX To Watch This Week [23 May 22] May 23, 2022 - The Australian market finally ended its month-long losing spree, closing marginally higher on the week after shaking off volatility and sharp corrections in US and Europe. Gains were driven by China’s sharper-than-expected bank rate cut and signs of the country finally easing its COVID-zero policy. The ASX200, ASX300, and ASX Ordinaries closed the week higher… Continue Reading
Stocks on the ASX To Watch This Week [16 May 22] May 16, 2022 - The Australian markets continued their downward trajectory in line with global markets with a sharp sell-off earlier in the week and a tentative recovery towards its end. As in the past few weeks, inflation, and a potential recession triggered by rate hikes continued to worry investors. The ASX200, ASX300, and ASX Ordinaries closed the week… Continue Reading
Stocks on the ASX To Watch This Week [2 May 22] May 2, 2022 - The Australian markets fell in line with global markets as investors digested potential economic slowdowns, unexpectedly high inflation, and China’s COVID situation. A risk-off sentiment took hold as US stocks closed their worst April in years after major companies showed signs of slowing growth. Meanwhile, potential lockdowns across China threatened to choke supply chains and… Continue Reading
Stocks on the ASX To Watch This Week [26 April 2022] April 26, 2022 - The Australian markets ended slightly in red territory for the week as they fight against inflation took center stage. Major central banks across the world echoed concerns and outlined the possibility of substantial rate hikes in May. Demand concerns emanated for the country’s materials sector from China’s current pandemic woes. The ASX200, ASX300, and the… Continue Reading
53 Stocks on the ASX 200 To Watch This Week [22 Nov 2021] November 22, 2021 - The three ASX indices (200, 300, and All Ordinaries) closed last week lower by 0.84%, 0.82%, and 0.75% respectively. Shares on the ASX declined in the earlier part of last week due to a warning from the RBA that it was looking to raise interest rates over time, and that people who were taking advantage… Continue Reading
Why Mesoblast Shares (ASX MSB) Is A Speculative Stock To Buy August 15, 2018 - Mesoblast Limited (ASX MSB; Nasdaq MESO) is a Melbourne-based leading global stem cell company focusing on R&D in regenerative cellular medicines. The Mesoblast share price has been falling since 2011 but has since stabilised in the $1.20 to $2.00 range in the past two years. Despite the company burning piles of cash each year, investors… Continue Reading

Are you looking for the best stocks to buy in 2021? We’ve put together a free report on 5 stocks that we think are the best buys on the ASX right now. Download it instantly here.

Information is provided ‘as is’ and solely for information purposes, not for trading purposes or advice.

MF & Co. Asset Management

MF & Co. Asset Management is a boutique investment firm offering Equity Capital Markets and derivative general advice & trade execution services.

We are specialists in advising and trading in Australian and US Equities, Index & Equity Options and Options on Futures.

Contact

Get In Touch

Australia
1300 889 603
International
+61 2 8378 7199
M-F: 8am-5pm

Suite 803, Level 8
70 Pitt St, Sydney, NSW 2000